Gate.io data on September 26th, Morgan Stanley released a report stating that Bubble Mart (09992.HK) and Giant Bio (02367.HK) will continue to be in a profit growth phase in the next two years. Both companies are in their early penetration stage, so they are less affected by mainland macro pressures. The report suggests that Bubble Mart is expected to record a sales increase of more than 60% in the third quarter, with its overseas stores' productivity subir in July and August compared to the previous quarter, driven by summer traffic and replenishment of popular products. Furthermore, the speed of opening stores in the mainland and overseas should accelerate from the third quarter. The bank believes that now is a good time for long-term investors to review their investment themes. The bank is confident in the company's third-quarter sales results and believes that new products launched in the fourth quarter and the first quarter of next year will support the stock price. As for Giant Bio (02367.HK), the bank expects the company's sales subir to reach 30% to 35% in the second half of the year, and the company stated that the third-quarter increase is roughly in line with the plan, which is positive news, especially as the company did not make much promotion in the off-season.
Ver originales
Esta página puede contener contenido de terceros, que se proporciona únicamente con fines informativos (sin garantías ni declaraciones) y no debe considerarse como un respaldo por parte de Gate a las opiniones expresadas ni como asesoramiento financiero o profesional. Consulte el Descargo de responsabilidad para obtener más detalles.
Morgan Stanley: Pinduoduo and GigaGen are in a profit upgrade cycle
Gate.io data on September 26th, Morgan Stanley released a report stating that Bubble Mart (09992.HK) and Giant Bio (02367.HK) will continue to be in a profit growth phase in the next two years. Both companies are in their early penetration stage, so they are less affected by mainland macro pressures. The report suggests that Bubble Mart is expected to record a sales increase of more than 60% in the third quarter, with its overseas stores' productivity subir in July and August compared to the previous quarter, driven by summer traffic and replenishment of popular products. Furthermore, the speed of opening stores in the mainland and overseas should accelerate from the third quarter. The bank believes that now is a good time for long-term investors to review their investment themes. The bank is confident in the company's third-quarter sales results and believes that new products launched in the fourth quarter and the first quarter of next year will support the stock price. As for Giant Bio (02367.HK), the bank expects the company's sales subir to reach 30% to 35% in the second half of the year, and the company stated that the third-quarter increase is roughly in line with the plan, which is positive news, especially as the company did not make much promotion in the off-season.